According to a new report, published by KBV research, The Global Infertility Drugs Market size is expected to reach $4.8 billion by 2028, rising at a market growth of 6.2% CAGR during the forecast period.
The Men market is registering a CAGR of 8.4% during (2022 - 2028). Human chorionic gonadotropin may be provided to men with low testosterone levels in order to regulate FSH and L.H. levels and boost sperm production. For up to six months, this medicine is administered intravenously three times each week.
The Hospital Pharmacy market is leading the segment in the Global Infertility Drugs Market by Distribution Channel in 2021; thereby, achieving a market value of $2.6 billion by 2028. This dominance may be linked to the rise in inpatient consultation visits and the need for doctor's prescriptions for medication purchasing.
The Aromatase Inhibitors market is experiencing a CAGR of 6.5% during (2022 - 2028). Letrozole is a non-steroidal, highly selective oral aromatase inhibitor (A.I.) that may block the conversion of androstenedione to estrone and testosterone to estradiol by reversibly binding to the rate-limiting enzyme P450 aromatase in the oestrogen biosynthesis pathway.
The North America market dominated the Global Infertility Drugs Market by Region in 2021; thereby, achieving a market value of $1.8 billion by 2028. The Europe market is poised to grow at a CAGR of 6% during (2022 - 2028). Additionally, The Asia Pacific market would witness a CAGR of 7% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/infertility-drugs-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, Bayer AG, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Ferring Holdings SA, Organon & Co. and Mankind Pharma Ltd.
By End User
By Distribution Channel
By Drug Class
By Geography
Companies Profiled
Unique Offerings 
